{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T09:52:20Z","timestamp":1711619540615},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Convenio de Investigaci\u00f3n. Dep. de Salut. Generalitat de Catalunya","award":["352\/05"],"award-info":[{"award-number":["352\/05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00415-016-8053-z","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T08:09:37Z","timestamp":1455264577000},"page":"722-729","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients"],"prefix":"10.1007","volume":"263","author":[{"given":"Elisabet","family":"Matas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Iniesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Romero-Pinel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alba","family":"Ma\u00f1\u00e9-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"8053_CR1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43:655\u2013661","journal-title":"Neurology"},{"key":"8053_CR2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285\u2013294","journal-title":"Ann Neurol"},{"key":"8053_CR3","doi-asserted-by":"crossref","unstructured":"PRIMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352:1498\u20131504","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"8053_CR4","doi-asserted-by":"crossref","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon-\u03b2-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS\/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-\u03b2-1a in relapsing MS. Neurology 56:1628\u20131636","DOI":"10.1212\/WNL.56.12.1628"},{"key":"8053_CR5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.10290","volume":"52","author":"J R\u00edo","year":"2002","unstructured":"R\u00edo J, Nos C, Tintor\u00e9 M et al (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52:400\u2013406","journal-title":"Ann Neurol"},{"key":"8053_CR6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.20224","volume":"56","author":"RA Rudick","year":"2004","unstructured":"Rudick RA, Lee JC, Simon J et al (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548\u2013555","journal-title":"Ann Neurol"},{"key":"8053_CR7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1212\/01.wnl.0000304040.29080.7b","volume":"70","author":"S Malucchi","year":"2008","unstructured":"Malucchi S, Gili F, Caldano M et al (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70:1119\u20131127","journal-title":"Neurology"},{"key":"8053_CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1191\/135248506ms1245oa","volume":"12","author":"F Gilli","year":"2006","unstructured":"Gilli F, Marnetto F, Caldano M et al (2006) Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12:47\u201357","journal-title":"Mult Scler"},{"key":"8053_CR9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1212\/WNL.0b013e3181b04c98","volume":"73","author":"D Hesse","year":"2009","unstructured":"Hesse D, Sellebjerg F, Sorensen PS (2009) Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 73:372\u2013377","journal-title":"Neurology"},{"key":"8053_CR10","doi-asserted-by":"crossref","unstructured":"Sottini A, Capra R, Serana F et al (2009) Interferon-Beta therapy monitoring in multiple sclerosis patients. Edcr Metab Immune Disord Drug Targets 9:14\u201328","DOI":"10.2174\/187153009787582379"},{"key":"8053_CR11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.52.6.1239","volume":"52","author":"F Deisenhammer","year":"1999","unstructured":"Deisenhammer F, Reindl M, Harvey J et al (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52:1239\u20131243","journal-title":"Neurology"},{"issue":"11","key":"8053_CR12","doi-asserted-by":"crossref","first-page":"e112758","DOI":"10.1371\/journal.pone.0112758","volume":"9","author":"E Matas","year":"2014","unstructured":"Matas E, Bau L, Mart\u00ednez-Iniesta M et al (2014) Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PLoS One 9(11):e112758. doi: 10.1371\/journal.pone.0112758","journal-title":"PLoS One"},{"key":"8053_CR13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol 58:840\u2013846","journal-title":"Ann Neurol"},{"key":"8053_CR14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"8053_CR15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","volume":"55","author":"C Confavreux","year":"1992","unstructured":"Confavreux C, Compston DA, Hommes OR et al (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55:671\u2013676","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8053_CR16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","volume":"122","author":"GA Schumacher","year":"1965","unstructured":"Schumacher GA, Beebe G, Kibler RF et al (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 122:552\u2013558","journal-title":"Ann N Y Acad Sci"},{"key":"8053_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp.73.2.148","volume":"73","author":"A Bertolotto","year":"2002","unstructured":"Bertolotto A, Malucchi S, Sala A et al (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148\u2013153","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8053_CR18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jir.1998.18.345","volume":"18","author":"G Antonelli","year":"1998","unstructured":"Antonelli G, Bagnato F, Pozzilli C et al (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 18:345\u2013350","journal-title":"J Interferon Cytokine Res"},{"key":"8053_CR19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jneuroim.2004.08.006","volume":"158","author":"F Gilli","year":"2005","unstructured":"Gilli F, Marnetto F, Caldano M et al (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158:195\u2013203","journal-title":"J Neuroimmunol"},{"key":"8053_CR20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-1759(01)00434-3","volume":"256","author":"A Bertolotto","year":"2001","unstructured":"Bertolotto A, Gilli F, Sala A et al (2001) Evaluation of bioavailability of three types of IFNb in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256:141\u2013152","journal-title":"J Immunol Methods"},{"key":"8053_CR21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00415-010-5844-5","volume":"258","author":"S Malucchi","year":"2011","unstructured":"Malucchi S, Gilli F, Caldano M et al (2011) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258:895\u2013903","journal-title":"J Neurol"},{"key":"8053_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/jnnp.2007.122549","volume":"79","author":"A Sominada","year":"2008","unstructured":"Sominada A, Hillert J (2008) Fogdell-Hahn. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralizing antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 79:57\u201362","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8053_CR23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/ene.12119","volume":"20","author":"M Romeoa","year":"2013","unstructured":"Romeoa M, Martinelli-Boneschib F, Rodeghera M et al (2013) Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing\u2013remitting multiple sclerosis patients. Eur J Neurol 20:1060\u20131067","journal-title":"Eur J Neurol"},{"key":"8053_CR24","doi-asserted-by":"crossref","unstructured":"Mezei Z, Bereczki D, Racz L et al (2012) Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing\u2013remitting multiple sclerosis? Neuropsychiatr Dis Treat 8:465\u2013473","DOI":"10.2147\/NDT.S36771"},{"key":"8053_CR25","doi-asserted-by":"crossref","unstructured":"S\u00e1 MJ, de S\u00e1 J, Sousa L (2014) Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey. Neurol Ther 3(2):89\u201399. doi: 10.1007\/s40120-014-0019-4 (eCollection 2014)","DOI":"10.1007\/s40120-014-0019-4"},{"key":"8053_CR26","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/brain\/awp228","volume":"132","author":"M Comabella","year":"2009","unstructured":"Comabella M, L\u00fcnemann JD, Rio J et al (2009) A type I interferon signature in monocytes is associated with poor response to interferon-B in multiple sclerosis. Brain 132:3353\u20133365","journal-title":"Brain"},{"issue":"4","key":"8053_CR27","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1371\/journal.pone.0001927","volume":"3","author":"L Baarsen van","year":"2008","unstructured":"van Baarsen L, Vosslamber S, Tijssen M et al (2008) Pharmacogenomics of interferon-B therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3(4):e1927. doi: 10.1371\/journal.pone.0001927","journal-title":"PLoS One"},{"key":"8053_CR28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","volume":"16","author":"RC Axtell","year":"2010","unstructured":"Axtell RC, de Jong BA, Boniface K et al (2010) T helper type I and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16:406\u2013412","journal-title":"Nat Med"},{"key":"8053_CR29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1742-2094-9-140","volume":"9","author":"A Hundeshagen","year":"2012","unstructured":"Hundeshagen A, Hecker M, Paap BK et al (2012) Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflamm 9:140. doi: 10.1186\/1742-2094-9-140","journal-title":"J Neuroinflamm"},{"issue":"4","key":"8053_CR30","doi-asserted-by":"crossref","first-page":"e94794","DOI":"10.1371\/journal.pone.0094794","volume":"9","author":"F Serana","year":"2014","unstructured":"Serana F, Imberti L, Amato MP et al (2014) MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS One 9(4):e94794. doi: 10.1371\/journal.pone.0094794","journal-title":"PLoS One"},{"key":"8053_CR31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/13550280701649670","volume":"13","author":"M Garcia-Montojo","year":"2007","unstructured":"Garcia-Montojo M, De Las Heras V, Bartolome M et al (2007) Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients. J Neurovirol 13:504\u2013512","journal-title":"J Neurovirol"},{"key":"8053_CR32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/WNL.47.4.889","volume":"47","author":"The IFNB Multiple Sclerosis study group and the","year":"1996","unstructured":"The IFNB Multiple Sclerosis study group and the (1996) University of British Columbia MS\/MRI analysis group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47:889\u2013894","journal-title":"Neurology"},{"key":"8053_CR33","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/01.WNL.0000129265.73259.9E","volume":"62","author":"S Malucchi","year":"2004","unstructured":"Malucchi S, Sala A, Gilli F et al (2004) Neutralizing antibodies reduce the efficacy of \u03b2IFN during treatment of multiple sclerosis. Neurology 62:2031\u20132037","journal-title":"Neurology"},{"key":"8053_CR34","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(03)14541-2","volume":"362","author":"PS Sorensen","year":"2003","unstructured":"Sorensen PS, Ross C, Clemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184\u20131191","journal-title":"Lancet"},{"key":"8053_CR35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1352458506070762","volume":"13","author":"A Sominanda","year":"2007","unstructured":"Sominanda A, Rot U, Suoniemi M et al (2007) Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13:208\u2013214","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8053-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8053-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8053-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T13:42:11Z","timestamp":1567604531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8053-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["8053"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8053-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}